This site is intended for healthcare professionals

Eli Lilly statement on the NIAID decision to pause enrollment in ACTIV-3 clinical trial of bamlanivimab as a treatment for COVID-19 in hospitalized patients.

Read time: 1 mins
Last updated:15th Oct 2020
Published:15th Oct 2020
Condition: Coronavirus/COVID-19 Infection
Type: drug
Register free for full access to